Neuraxis (NRXS) Common Equity (2022 - 2025)
Neuraxis (NRXS) posted Common Equity of $3.4 million for Q4 2025, up 48.77% sequentially from $2.3 million in Q3 2025, and up 64.4% YoY from $2.1 million in Q4 2024.
Neuraxis (NRXS) Common Equity (2022 - 2025) Analysis & Trends
Neuraxis has reported Common Equity for 4 years, with the latest figure at $3.4 million in Q4 2025.
- Quarterly Common Equity rose 64.4% year-over-year to $3.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.4 million (up 64.4% YoY) and the FY2025 annual result came in at $3.4 million, up 64.4% from the prior year.
- Common Equity climbed to $3.4 million in Q4 2025 per NRXS's latest filing, from $2.3 million in the prior quarter.
- Over five years, Common Equity peaked at $4.3 million in Q2 2025 and troughed at -$10.0 million in Q2 2023.
- A 4-year average of -$2.2 million and a median of -$1.8 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity sank 186.26% in 2023, then surged 247.36% in 2024.
- Over 4 years, Common Equity stood at -$5.6 million in 2022, then soared by 74.82% to -$1.4 million in 2023, then soared by 247.36% to $2.1 million in 2024, then soared by 64.4% to $3.4 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $3.4 million, $2.3 million, and $4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.40 Mn |
| Sep 30, 2025 | 2.28 Mn |
| Jun 30, 2025 | 4.25 Mn |
| Mar 31, 2025 | 258,479.00 |
| Dec 31, 2024 | 2.07 Mn |
| Sep 30, 2024 | -1.79 Mn |
| Jun 30, 2024 | -5.26 Mn |
| Mar 31, 2024 | -3.18 Mn |
| Dec 31, 2023 | -1.40 Mn |
| Sep 30, 2023 | -1.06 Mn |
| Jun 30, 2023 | -9.98 Mn |
| Mar 31, 2023 | -7.75 Mn |
| Dec 31, 2022 | -5.57 Mn |
| Sep 30, 2022 | -5.56 Mn |
| Jun 30, 2022 | -3.49 Mn |